Skip to main content

Table 5 Laboratory values at baseline (BL) and week-12 (W12)

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

 

All

Walk

Strength-Walk

BL

W12

p

BL

W12

p

BL

W12

p

Total Cholesterol (mg/dL)

196 (163–236)

186 (162–215)

0.018

190 (157–229)

180 (151–214)

0.042

217 (174–237)

191 (165–232)

n.s.

HDL-Cholesterol (mg/dL)

46 (34–54)

47 (36–56)

n.s.

45 (34–55)

47 (35–56)

n.s.

46 (33–56)

45 (35–59)

n.s.

LDL-Cholesterol (mg/dL)

124 (106–155)

108 (93–139)

0.004

116 (96–148)

103 (89–138)

0.033

147 (120–164)

121 (106–144)

0.031

Triglycerides (mg/dL)

143 (111–201)

131 (93–200)

n.s.

142 (101–222)

112 (80–205)

n.s.

137 (107–210)

165 (121–283)

n.s.

Glucose (mg/dL)

85 (78–92)

82 (79–93)

n.s.

85 (74–92)

81 (79–92)

n.s.

86 (80–93)

82 (78–93)

n.s.

Insulin (mg/dL)

11.8 (7.9-16.5)

13.0 (8.0-16.9)

n.s.

10.2 (5.8-17.0)

13.8 (6.6-17.2)

n.s.

13.1 (9.9-15.2)

10.3 (8.6-18.8)

n.s.

HOMA-Index

2.8 (1.6-3.4)

2.7 (1.7-4.1)

n.s.

2.3 (0.9-3.7)

2.8 (1.2-4.1)

n.s.

3.0 (2.1-3.3)

2.3 (1.8-5.0)

n.s.

HbA1c (%)

5.3 (5.1-5.8)

5.5 (5.3-5.6)

n.s.

5.2 (5.0-5.7)

5.3 (5.1-5.6)

n.s.

5.5 (5.3-5.9)

5.5 (5.5-6.0)

n.s.

CD4+ T-cells/μL

577 (407–726)

559 (445–715)

n.s.

485 (365–686)

557 (365–684)

n.s.

642 (527–740)

587 (481–796)

n.s.

CD8+ T-cells/μL

821 (652–914)

747 (566–975)

n.s.

766 (581–872)

743 (632–950)

n.s.

916 (783–1349)

747 (561–1090)

n.s.

VACS index

12 (5–19)

12 (0–21)

n.s.

16 (6–24)

17 (3–22)

n.s.

9 (0–12)

10 (0–18)

n.s.

  1. Values are expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
  2. HOMA Homeostasis Model Assessment, VACS Veterans Ageing Cohort Study